NCT03992066View on ClinicalTrials.gov

Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

May 28, 2019

Primary Completion Date

May 5, 2020

Study Completion Date

July 15, 2020

Conditions
Anemia Associated With Chronic Kidney Disease
Interventions
DRUG

Vadadustat

oral 150 mg tablet

DRUG

Darbepoetin alfa

solution intravenous injection

DRUG

Epoetin alfa

solution for intravenous injection

Trial Locations (10)

32809

Research Site, Orlando

33133

Research Site, Miami

33140

Research Site, Miami Beach

33308

Research Site, Fort Lauderdale

37404

Research Site, Chattanooga

64111

Research Site, Kansas City

73130

Research Site, Midwest City

80230

Research Site, Denver

92025

Research Site, Escondido

02903

Research Site, Providence

Sponsors
All Listed Sponsors
lead

Akebia Therapeutics

INDUSTRY

NCT03992066 - Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease | Biotech Hunter | Biotech Hunter